Chapter

Antiviral Strategies

Volume 189 of the series Handbook of Experimental Pharmacology pp 85-110

Viral Protease Inhibitors

  • Jeffrey AndersonAffiliated withDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts
  • , Celia SchifferAffiliated withDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts
  • , Sook-Kyung LeeAffiliated withUNC Center For AIDS Research, University of North Carolina at Chapel Hill
  • , Ronald SwanstromAffiliated withUNC Center For AIDS Research, University of North Carolina at Chapel Hill Email author 

* Final gross prices may vary according to local VAT.

Get Access

This review provides an overview of the development of viral protease inhibitors as antiviral drugs. We concentrate on HIV-1 protease inhibitors, as these have made the most significant advances in the recent past. Thus, we discuss the biochemistry of HIV-1 protease, inhibitor development, clinical use of inhibitors, and evolution of resistance. Since many different viruses encode essential proteases, it is possible to envision the development of a potent protease inhibitor for other viruses if the processing site sequence and the catalytic mechanism are known. At this time, interest in developing inhibitors is limited to viruses that cause chronic disease, viruses that have the potential to cause large-scale epidemics, or viruses that are sufficiently ubiquitous that treating an acute infection would be beneficial even if the infection was ultimately self-limiting. Protease inhibitor development is most advanced for hepatitis C virus (HCV), and we also provide a review of HCV NS3/4A serine protease inhibitor development, including combination therapy and resistance. Finally, we discuss other viral proteases as potential drug targets, including those from Dengue virus, cytomegalovirus, rhinovirus, and coronavirus.